PR90712

Bioelectronica Announces Hypercell(TM) Expansion for Antibody Discovery, Closing of Oversubscribed Series A Financing, Powering Local Hiring Growth and Expansion of Facilities in Reno

RENO, Nev., July 19, 2021 /PRNewswire=KYODO JBN/ --

- Expansion of Hypercell(TM) for biopharma discovery with software.

- Establishment of a second site increased lab capacity by over 45% and

engineering capacity by over 70%.

Bioelectronica(R) Corporation ("Bioelectronica") announced today that it has

secured an undisclosed amount in its Series A financing round due to increased

interest in Hypercell(TM), a new hardware tool that can be used to discover new

antibodies using computer vision, which are industrially and technologically

timely and relevant. This is proven by Hypercell's recent win of an industry

award at ISAC, a leader in flow cytometry. The judges and audience unanimously

agreed that Bioelectronica's approach was the most innovative compared to its'

peers.

Logo - https://mma.prnewswire.com/media/1447740/bioelectronica_Logo.jpg  

"One way to think of Hypercell(TM) and digital biology is as a video-game

console, in which researchers can use software programming to develop new

software-controlled workflows for biopharma applications like antibody

discovery and other functional assays for biopharma applications" said Jonathan

Hull, Co-Founder and CEO. "I personally like analogies with Nintendo(R) because

I'm a Tetris fan, but that's subjective", said Hull.

The funding has accelerated Bioelectronica's path and advanced plans to open a

third research site in Nevada, effectively increasing the Company's laboratory

space and engineering capacity by 45% and 70%, respectively. It also allowed

the Company to continue to grow their team. Since January 2020, Bioelectronica

has grown their team by 56%. The Company has been actively hiring top local

talent in Reno, with 62% of all employees recruited from the University of

Nevada, Reno. This milestone is a major move for Bioelectronica on its mission

to develop Hypercell(R), a next-generation platform that uses patent-pending

electrofluidic hardware, reagents and data science to expedite biopharma

discovery and production workflows.

"As one of the fastest growing local biotech startups, we have been focused on

hiring the best local talent," says Hull. "As we continue to grow our team, we

increased our operational footprint with a new facility and are investing in

employee growth and development to ensure that they are geared for success."

"It's been amazing seeing the growth trajectory of Bioelectronica," says

Orlando Gonzalez, U.S. Army Captain (ret) and Advisor to Bioelectronica. "The

company continues to sustain operational growth and has promoted an excellent

team culture. This is evidenced by the Company's quarterly leadership

development workshops, which have given me a true opportunity to engage with

the team. This team has tremendous potential to take Bioelectronica to the next

level."

New hires include talent technical and commercial talent from Hamilton

robotics, VWR and Europhins. Roger Chen, Founder and CTO, was previously at

Roche and is a successful founder and entrepreneur. Hull commented, "I'm very

proud of our team, and am optimistic about our reach into the research market

in the coming years. Our culture is to train and promote from within, and it's

already paying off. Our team is outstanding."

The company is exploring offices in Asia and Europe to keep pace with the

fast-growing demand for research and new antibodies due to the pandemic. "While

Reno has been a great place to incubate, we may need to consider new offices.

We hope to soon begin work on new cell therapies, provided we can secure the

growth-capital that we need to continue to expand at this pace" says Hull.

About Bioelectronica

Bioelectronica(R) is a research-stage biotechnology company building

intelligent, digital tools for biopharama discovery, cell screening and cell

sorting. Bioelectronica's platform technology combines computer vision,

biochemical reagents and consumer electronics to enable unique

software-controlled workflows. We believe that by transforming biochemistry

through digital innovation, we fundamentally change the speed and price of

therapeutics discovery and development. For more information on how your

workflow can benefit from Bioelectronica's step change innovation, contact

Jonathan Hull or the team at hello@bioelectronica.com. Bioelectronica(R) and

Hypercell(R) are registered trademarks of Bioelectronica. Hypercell(R) is For

Research Use Only.

Follow Bioelectronica at www.bioelectronica.com, on LinkedIn at

www.linkedin.com/company/bioelectronica, and on Twitter @singlecellsort (https://c212.net/c/link/?t=0&l=en&o=3231606-1&h=2316578601&u=https%3A%2F%2Ftwitter.com%2Fsinglecellsort&a=%40singlecellsort).

SOURCE  Bioelectronica